|
Age, years
|
67 (50, 81)
|
|
Female
|
188 (30.6%)
|
|
African American
|
26 (4.2%)
|
|
Body mass index, kg/m2
|
27.7 (22.5, 36.9)
|
|
Medical history
|
|
Hypertension
|
544 (88.5%)
|
|
Congestive heart failure
|
243 (39.5%)
|
|
Left ventricular ejection fraction, %
|
60 (35, 60)
|
|
Myocardial infarction
|
110 (17.9%)
|
|
Prior cardiac surgery
|
110 (17.9%)
|
|
Diabetes
|
202 (32.8%)
|
|
Current smoking
|
88 (14.3%)
|
|
Chronic obstructive pulmonary disease
|
64 (10.4%)
|
|
Peripheral vascular disease
|
170 (27.6%)
|
|
Preoperative medication use
|
|
Statin
|
416 (67.6%)
|
|
ACE inhibitor
|
192 (31.2%)
|
|
Baseline laboratory data
|
|
Creatinine, mg/dl
|
1.01 (0.74, 1.60)
|
|
eGFR, ml/min/1.73 m2
|
72.8 (38.5 96.7)
|
|
Hematocrit, %
|
34 (25, 43)
|
|
Perioperative atorvastatin treatment assignment
|
308 (50%)
|
|
Procedure characteristics
|
|
CABG surgery
|
301 (48.9%)
|
|
Valve surgery
|
397 (64.6%)
|
|
Cardiopulmonary bypass use
|
435 (70.7%)
|
|
Cardiopulmonary bypass time, min
|
110.0 (0, 211.6)
|
|
Aortic cross clamp use
|
291 (47.3%)
|
|
Aortic cross clamp time, min
|
0 (0, 139.6)
|
|
Intraoperative fluids
|
|
Intravenous crystalloid, mL
|
1600 (1000, 3000)
|
|
Intravenous hydroxyethyl starch, mL
|
0 (0, 0)a
|
|
Urine output, mL
|
430 (175, 946)
|
|
Arterial lactate, maximum intraoperative, mmol/L
|
1.7 (0.9, 3.8)
|
|
Length of surgery, hours
|
5.1 (3.6, 7.8)
|
